Loading
A phase 2 trial of SKB264+SKB118 in non-small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07697586 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 206 participants planned, started 2026-08-07 and due to reach its primary completion in 2028-08. Interventions recorded: SKB264+SKB118.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/